#LB0004 #EULAR2022 Positive Phase 2 results in #lupus! Deucravacitinib, a TYK2-inhibitor reported significantly more SRI-4 response rates in DEUC vs PBO. PBO: 34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety. Will proceed to Phase 3 @RheumNow https://t.co/cZLv6bbHer